Category Archives: Cell Biology

HPU Students, Faculty and Staff Recognized for Research and Innovation – High Point University

HIGH POINT, N.C., Aug. 14, 2020 Members of the High Point University community frequently conduct, publish and share research and creative works in a variety of ways. Below is a recap of recent research initiatives.

HPU Student, Alumna and Faculty Research Featured in National Scientific Journal

Casey Garr, HPU alumna; Candyce Sturgeon, HPU rising senior; Dr. Veronica Segarra, HPU assistant professor of biology; and Noah Franks, student at Penn Griffin School of the Arts in High Point, North Carolina; recently conducted research that was published in Autophagy, a national scientific journal.

The study, titled, Autophagy as an on-ramp to scientific discovery, examines HPUs Cell Art Collaborative program to gain understanding around how the recruitment of highly creative students into STEM fields through connections to art can be a first step in defining a specialized career path that leads to a valuable and unique contribution to science.

In addition to providing experiential learning opportunities for students at HPU to conduct hands-on research and co-author peer-reviewed articles, the Cell Art Collaborative program encourages students in the local community to explore careers that incorporate both science and art, says Segarra. This initiative continues to facilitate conversations around STEAM-based learning environments for educators to take advantage of a wider range of student talents and interests, preparing them to go forth into society as the creative thinkers and problem solvers the world needs.

HPU Students Research Featured in CBE: Life Sciences Education Journal

Clara Primus, a rising junior majoring in biology and Bonner Leader at HPU, recently collaborated with prominent scientists at the Mayo Clinic, University of California Davis and Northwestern to conduct research that was published in CBE: Life Sciences Education, a quarterly journal published by the American Society for Cell Biology. The article, titled, Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations, examines how scientific societies can contribute to a diverse and inclusive workforce.

The research compares and contrasts the broad approaches that scientific societies within the National Science Foundation-funded Alliance to Catalyze Change for Equity in STEM Success (ACCESS) use to implement and assess their travel award programs for underrepresented minority (URM) trainees. Findings will improve collaboration and better position scientific societies to begin addressing some of these questions and learning from each other.

The recommendations included in this research shed light on how even scientific societies can be allies in furthering inclusion efforts, said Primus. Ive spent nearly two years studying equity and diversity, and I hope that I can take the knowledge Ive learned from all of my research to educate my peers at HPU.

HPU Exercise Science Professor Publishes Statement for the American Heart Association

Dr. Colin Carriker, assistant professor of exercise science in HPUs Congdon School of Health Sciences, recently co-authored an American Heart Association (AHA) scientific statement on medicinal and recreational cannabis use published in Circulation.

The statement critically reviews the use of medicinal and recreational cannabis from a clinical but also a policy and public health perspective by evaluating its safety and efficacy profile, particularly in relation to cardiovascular health. The purpose of this scientific statement was to explore the evidence and science pertaining to medical marijuana, recreational cannabis and cardiovascular health to provide physicians and health care providers with the information available to date. While cannabis may have some therapeutic benefits, these do not appear to be cardiovascular in nature. Health care providers would benefit from increased knowledge, education and training pertaining to various cannabis products and health implications, including recognition that cannabis use may, in fact, exacerbate cardiovascular events or other health problems. In this regard, the negative health implications of cannabis should be formally and consistently emphasized in policy, while aligning with the American Heart Associations commitment to minimizing the smoking and vaping of any products and banning cannabis use for youth.

It was an honor to work alongside such a high-quality team of researchers, says Carriker. I want to especially thank our committee chairs, Dr. Robert L. Page II and Dr. Larry A. Allen, as their extraordinary leadership and organization were integral components in the completion and publication of this AHA scientific statement. We publish these statements to counterbalance and debunk misinformation because the public requires high-quality information about cannabis from reputable organizations such as the American Heart Association.

Carriker is the advocacy ambassador for the American Heart Associations Council on Lifestyle and Cardiometabolic Health and served as a member of the writing committee tasked with writing this AHA Scientific Statement initiated by the AHAs Council on Clinical Cardiology.

Read the original here:
HPU Students, Faculty and Staff Recognized for Research and Innovation - High Point University

2020 Study on the Innovations in Live Cell Imaging, Portable Imaging and Screening Devices, and Digital Screening and Diagnostics Solutions -…

The "Innovations in Live Cell Imaging, Portable Imaging and Screening Devices, and Digital Screening and Diagnostics Solutions" report has been added to ResearchAndMarkets.com's offering.

This latest issue of Advanced MedTech Technology Opportunity Engine (TOE) profiles a wide range of innovations from the advanced medical device and imaging industry. The innovations span the breadth of market segments in the MedTech space, from advanced holotomographic microscopy, holographic microscopy, portable screening, and diagnostic devices such as portable X-ray, breast, or lung cancer detection device, and smartphone-based retinal imaging and wound management solutions.

In addition, innovations in AI-based diagnostic devices, novel surgical robotic systems, skin patch for drug delivery, and vital sign monitoring, non-contact patient monitoring are also covered. These innovations portray the diversity in their technology readiness levels, indicating an immediate or potential market impact. The growth opportunities for all these advanced medical device technologies are also covered in this issue.

The Advanced MedTech TOE analyzes and reports new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, ultrasound, X-ray, neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology, and image-guided surgery, and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered.

Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms.

Story continues

Key Topics Covered:

Innovations in Medical Devices & Imaging

Holotomographic Microscopy with 3D Fluorescence Imaging

Automated Long-term Holotomographic Live Cell Imaging

Growth Opportunity: Holotomographic Microscopy has Applications in Cell Biology, Disease Diagnosis, and Drug Discovery

Holographic Microscope for Live Cell Imaging Inside an Incubator

Holographic Microscopy Modules for Observing Cells in Suspension and Adherent Cell Cultures

Transmission Holographic Microscopy for Advanced Biological Imaging Applications

Growth Opportunity: Holographic Microscopy Reduce Cost, Time, Complexity and Size of Equipment

Saline Enhanced Radiofrequency Ablation Therapy for Treating Ventricular Tachycardia

Growth Opportunity: Saline Enhanced Radiofrequency Ablation Reduces Time and Complexity and Increases Safety of Treatment

Wireless, Compact and Portable X-ray Machines

Growth Opportunity: Portable X-ray Device Has Growth Opportunities in Medical, Veterinary and Dental Imaging

Portable, Home-use Fertility Tracking Device

Growth Opportunity: Use of AI to provide Accurate and Personalized Insights

Portable Screening Test for Breast Cancer Detection

Growth Opportunity: Accurate Diagnosis of Breast Cancer to Enable Better Patient Survival Rates

Automated Screening Tool for Detecting Diabetic Retinopathy

Growth Opportunity: Early Diagnosis of Diabetic Retinopathy to Minimize Risk of Vision Loss among Patients

Smartphone-based Retinal Imaging Device for Diabetic Retinopathy Diagnosis

Growth Opportunity: Ease of Use across Different Clinical Settings to Improve Patients' access to Diabetic Retinopathy Screening

AI-powered Platform for Detecting Myocardial Infarction

Growth Opportunity: Fast and Precise Diagnosis to Facilitate Improved Patient Health Outcomes

Next-Generation Robotic System for Minimally Invasive Procedures

Growth Opportunity: Versatile and Cost-effective System for Improving Hospital Efficiency and Clinical Outcomes

Smartphone-enabled Application for Wound Care Management

Growth Opportunity: Use of Artificial Intelligence for Providing Comprehensive Wound Assessment

Non-invasive Breath Test for Lung Cancer Detection

Growth Opportunity: Early and Accurate Diagnosis of Lung Cancer to Enable Better Patient Survival Rates

Imaging Technology for Cardiovascular Disease

Growth Opportunity: Solution for Pre-operative Planning for Heart Valve Surgeries

First Open-sourced Electronic Health Records

Growth Opportunities: Healthcare Ecosystem Platform Empowering Patients, Hospitals, and Medical Research Institutions

Wearable Smart patch for Needle-free Drug Delivery

Growth Opportunities: Smartpatch for Delivery of Macromolecules in Patients with Chronic Diseases

Highly Sensitive IoT-enabled Smart Tattoo Sensor for Vital Sign Monitoring

Growth Opportunities: Smart Tattoo Sensor to Create Connected Health Ecosystem with all Stakeholders

Non-contact Vital Signs Monitoring Device

Growth Opportunities: Long-term Vital Sign Monitoring Device for Home and Hospital Setting

Machine Learning-based Mobile Application for Diagnosis

Growth Opportunities: Health Application with Advanced Technology for Multiple Disease Screening

Acoustic Device with AI Capabilities to Predict Heart Disorders

Growth Opportunities: Smart Stethoscope to Enable Physician to Predict Heart Disorders at Clinics

Automated and Intelligent System for Ventilated Patients

Growth Opportunities: Automated and Closed Hygiene System for COVID-19 Patients

Next-generation Smartphone Compatible Ophthalmoscope

Growth Opportunities: Smartphone-based Ophthalmoscope for Preventing Blindness

Robotic Surgical System for Vitreoretinal Procedures

Growth Opportunity: High Precision Treatment and Ability to Limit Post-procedural Complications to Help in Improving Patient Outcomes

Portable Retinal Imaging Device for Performing Contactless Eye Exams

Growth Opportunity: AI-based Solution to Enable Early and Faster Diagnosis

Industry Contacts

For more information about this report visit https://www.researchandmarkets.com/r/ojhxxu

View source version on businesswire.com: https://www.businesswire.com/news/home/20200814005407/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Here is the original post:
2020 Study on the Innovations in Live Cell Imaging, Portable Imaging and Screening Devices, and Digital Screening and Diagnostics Solutions -...

How do we ensure Global Health research leads to practical solutions at the local level? – BugBitten – BMC Blogs Network

While every research is good, very few resonate well among the general public. The public in LMICs will probably only get on board research that will directly benefit them. Credit: Paul Adepoju.

For my masters degree in cell biology and genetics, I screened for gene polymorphisms in adults co-infected with helminth and latent tuberculosis in a rural community in Nigerias south west region. The journey from my university (the University of Ibadan) to the study site took several hours and along the way, I began to ask myself why my supervisor, Dr Chiaka I. Anumudu, was attracted to the particular study site.

The days that we spent at the site were quite eye opening for me as I found myself in Eggua village, a peaceful community which, I found out, largely relies on the Yewa river for daily life.

I did not grow up very rich but no matter how much I thought we lacked, my family never had to bathe, drink or wash using water from a river that some people do urinate and defecate near resulting in haematuria and other symptoms of schistosomiasis. Even though we were providing praziquantel for those that had the disease, I knew that it may not stop future episodes of the disease as the people will still go back to the river which is the main source of infection.

On our last day at the village, a PhD grad student that is also a member of the research team took me round the village. We saw huts, farmlands and buildings inhabited by individuals of all age groups. Then we proceeded to the river because he needed the coordinates for his thesis. Out of my curiosity and probably naivety, I asked aloud why will people be drinking or doing anything in the water the popular Yewa River? A villager passing by heard and smiled. He boasted that at birth, he was bathed with the water from the river and he continues to drink it to this day.

Almost every household in the community, including the kings, has had at least one person that suffered from schistosomiasis, making it a perfect study site for studies focusing on schistosomiasis.

But I began to ask myself what direct benefit will the man that has been drinking the water from birth enjoy from my work that is on gene polymorphism? I also asked myself whether my line of research would result in any direct benefit to the community.

A quicker solution to the schistosomiasis crisis in the community would be the provision of safer and cleaner sources of water. Even though I overheard my supervisor talking about plans to get the community the much needed assistance from government and other parties to achieve this, she was quick to tell me that it is not researchers job to be providing water to communities.

But what about making the water safer and unable to allow vectors of schistosomiasis to thrive? I responded.

She drew my attention to the world of molluscicide. While reading up this particular line of research, I noticed that the idea has been floating around since the 1950s, or probably much earlier.

Walter L. Newton and Willard T. Haskins in July 1953 described the dosage-mortality responses of some strains of Australorbis Glabratus to sodium pentachlorophenate.

In fact the World Health Organization (WHO) recommends that snail control be implemented as a key

component of any schistosomiasis control and elimination strategy. Currently the WHO has licenced only one molluscide compound for the control of snails in areas affected by schistosomiasis, called Niclosamide.The WHO has developed guidelines on the evaluation of molluscicides and a manual for the field application of molluscicide. However it is known that the application of Niclosamide may not be appropriate or feasible for all transmission settings, though safe for humans and mammals, it is known to be toxic to other aquatic animals such as fish and ampibians. It also biodegrades rapidly meaning it can not be applied to large expanses of water, such as big lakes. Whilst snail control is a key component for schistomiasis elimination, further reseach and development is needed to produce low-cost, suitable and effective snail control and transmission control strategies.

For example a 2018 review mentioned Euphorbia milii var. hislopii, described by Eugene Ursch and Jacques Dsir Leandri in 1955, as the most promising phytochemical molluscide for use in official schistosomiasis control programs.

Considering the few number of scientific publications on molluscicides since 2018, it may take several years or decades before an effective molluscicide will emerge and may still take more years for such to become available to the people of Eggua village and others around the world that are still dealing with schistosomiasis.

This is not something that is peculiar to schistosomiasis as it seems like the situation is the same for several other parasitic diseases. While the body of knowledge on various parasites, vectors and associated diseases are expanding at a very rapid rate, many of the diseases continue to kill more people.

Few weeks ago, I visited one of Africas highly respected experts in virology, Prof Oyewale Tomori, and he drew my attention to how science is getting sidelined in the scheme of things and the general public, especially in several low and middle-income countries are struggling to understand the importance and relevance of the science ecosystem.

He noted that even though lots of research papers are published annually on malaria resulting in the emergence of several professors of malaria, their findings are yet to transform into the end of malaria as most of the successes recorded in malaria control are attributed to expanding access to antimalarial drugs and insecticide-treated nets and not local malaria researches. Little or nothing from the local research ecosystem has significantly changed or helped the malaria response.

As COVID-19 continues to be the center of attention as far as science is concerned and researchers working on the disease are publishing their research at a faster rate than for other diseases, I believe that it should serve as a key moment for researchers in the parasite and vector-borne diseases community to think of reevaluating their research priorities and consider not just how their science will provide additional knowledge regarding their research interest, but will also provide direct and quick benefit to the people that are living with the disease that we are researching.

Tens of thousands of people, largely young children, die annually of malaria. They will not benefit directly from research exploring the genome of the malaria parasite or its vector, while indirect impact might take decades if there will be any at all.

I know that it is not every researcher that can focus on solutions but I believe that the community needs to be frank with itself and find out how solutions-focused research can be better prioritised because no matter how much attention that COVID-19 is getting, malaria and other disease burdens remain, so do the whole spectrum of vector-borne parasitic diseases.

The villager that overheard me thinking aloud regarding the awful state of the water that he and other members of Eggua community rely on may not understand what single nucleotide polymorphisms mean and may get bored just listening to me explain. But I believe he and other residents will be excited to know about a molluscicide that will ensure that the Yewa River no longer harbors any vector of the parasitic infection that has plagued their community for decades.

Simply put, even when the attention of the global science community is on demystifying COVID-19, societies that are directly benefiting from our research will still be interested in the science that affects their daily lives and could be active advocates for such research even when government policies and priorities fluctuate and change. As a global health research community, is it time for us to rethink how we involve societies in our research, so that together we can find practical solutions aimed at improving their lives?

Read more here:
How do we ensure Global Health research leads to practical solutions at the local level? - BugBitten - BMC Blogs Network

Cell Imagers Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 – Bulletin Line

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Cell Imagers Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Cell Imagers Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Cell Imagers market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Global Cell Imagers Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2019 to 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Cell Imagers Market are:

Competitive Landscape of the Cell Imagers Market:

The market for the Cell Imagers industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Global Cell Imagers Market, By Product

Equipment Consumables Software

Global Cell Imagers Market, By Application

Drug Discovery Developmental Biology Cell Biology Stem Cell Biology

Global Cell Imagers Market, By End User

Academic & Research Institutes Pharmaceutical & Biotechnology Companies Academic & Research Institutes

Regional Analysis of Cell Imagers Market:

A brief overview of the regional landscape:

From a geographical perspective, the Cell Imagers Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Cell Imagers Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read more:
Cell Imagers Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

Hamilton Thorne to Announce Q2 2020 Financial Results and Hold Conference Call on August 20, 2020 – GlobeNewswire

BEVERLY, Mass. and TORONTO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three- and six-month periods ended June 30, 2020 before market open on Thursday, August 20, 2020. The press release, with accompanying financial information, will be posted on the Companys website at http://www.hamiltonthorne.ltd and on http://www.sedar.com.

The Company will follow with a conference call on the same day at 11:00 a.m. EDT to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929 from other locations, and requesting Conference ID 2789186. A recording of the call will be available on Hamilton Thornes website shortly after the call.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thornes customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Read more:
Hamilton Thorne to Announce Q2 2020 Financial Results and Hold Conference Call on August 20, 2020 - GlobeNewswire

Dave Schubert, Salk scientist who aimed to unlock mysteries of human body, dies at 77 – The San Diego Union-Tribune

Renowned cell biologist and Salk Institute researcher Dave Schubert, whose research helped identify chemicals that can slow the progression of Alzheimers and related diseases, died last week at a local hospital. He was 77.

The La Jolla resident had been undergoing tests since early July to diagnose a case of severe anemia, but he had continued to work in his lab at Salk. On Aug. 4, he was diagnosed with B cell lymphoma and hospitalized at UC San Diego Thornton Hospital, where he died just two days later on Aug. 6.

His sudden passing came as a shock to family and friends of the vital and active scientist who had been an Ironman triathlete and ultra-marathon runner in his earlier years, according to his wife of 32 years and research partner, Dr. Pamela Maher, who is a senior staff scientist at Salk.

Among his friends, they all thought hed be the last of the old guard to go, Maher said. People thought of him as a fighter, that hed battle it and overcome it. But it was too late.

Salk Institute researcher and professor David Schubert and his wife, Dr. Pamela Maher, who is a senior staff scientist at Salk.

(Courtesy of Salk Institute)

In his more than five decades of work at Salk, Schubert became known for the development of novel screening techniques that allowed his team to identify naturally occurring chemicals that can slow or prevent the neurological damage that occurs in neurodegenerative disorders, such as Alzheimers disease.

We are deeply saddened by the news of Daves passing, Salk President Rusty Gage said in statement. He was one of the earliest graduate students at Salk and spent close to 55 years of his scientific career here. Dave will be greatly missed and we are forever thankful for his contributions to our research community.

Maher described her husband as a classic, old-school scientist with a reputation for integrity. He was driven by his passion for helping others, rather than a desire to seek out the largest research grants. Jan Lewerenz, a senior physician at Ulm University Hospital in Germany, and one of Schuberts former postdoctoral researchers, said she would always remember Schubert as one of the best human beings I had the privilege to know.

Without him, my life would have been different, Lewerenz said. Whenever I have to deal with slimeballs, I am reminded of his integrity and honesty. The world, now more than ever, is in desperate need of people like Dave. He will always be my role model for how to navigate the murky waters of academic research without selling ones soul.

Schubert was born in 1943 in Indianapolis and earned his bachelors degree in chemistry from Indiana University in 1965. He arrived at Salk later that year as a graduate student, while working on his doctorate in cell biology at UC San Diego. At Salk, Schubert started out in the lab of the late Salk professor and immunologist Melvin Cohn. From there, he moved to Paris to do his postdoctoral fellowship at the Pasteur Institute under the direction of Nobel laureate Franois Jacob. He returned to Salk in 1970 as a member of the faculty.

Schubert established the first neurobiology laboratory at Salk, where he developed and characterized a large number of nerve, glial and muscle cell lines that have served as the basis for numerous important discoveries by labs around the world. He also served as a professor and the head of Salks Cellular Neurobiology Laboratory until his passing. His diverse body of research included studying factors influencing the health and development of nerve and muscle cells, studies on neuroblastoma cancer and research on genetically modified crops, according to Salk officials.

In recent years at Salk, Schubert and Maher developed a novel screening technique to test for naturally occurring chemicals that can prevent the type of nerve cell death found in neuro-degenerative diseases. This led to the establishment of the first medicinal chemistry lab at Salk where he worked to make derivatives of the neuro-protective natural products that have improved medicinal, chemical and pharmacological properties over the parent compounds.

One such natural product is fisetin, which can be found in strawberries. It prevents memory and learning deficits in mouse models of Parkinsons and Alzheimers diseases. A synthetic derivative of fisetin is now undergoing the studies necessary for moving into clinical trials. Also, Schubert and Maher found that a synthetic derivative of the curry spice curcumin, called J147, improves behavioral and pathological symptoms associated with Alzheimers, traumatic brain injury and stroke. This compound is currently in a phase 1 clinical trial for the treatment of Alzheimers.

Maher said their Alzheimers derivitive research was an unusual project for Salk, in that all of its development, from the earliest ideas to the trial phase, was conducted in-house. Usually, the research gets passed on to drug development firms much earlier.

He will be disappointed that he doesnt get to see what happens, but getting it that far was really quite a feather in his cap, Maher said.

Besides his research work, Schubert also served as a member of the County of San Diego Scientific Advisory Board and the National Water Reuse Panel for San Diego County. He was also an environmental justice advocate who wrote frequent op-ed pieces on the topic for The San Diego Union-Tribune and most recently had reached out to the city of San Diego and San Diego Unified School District to encourage them to stop using Roundup weed-killer because of its possible impact on the environment.

Schubert is survived by Maher, his son Bruno Schubert and three grandchildren. There are no memorial services planned at this time. Maher said her husband will be cremated and his ashes will be scattered under his favorite plants in their garden.

This is what he told people that he wanted, Maher said. Dave loved the garden and spent a lot of time working in it as well as enjoying it. As with the science, he was very passionate about the garden and actually was breeding plants that are endangered in the wild, to help keep them going.

Read the rest here:
Dave Schubert, Salk scientist who aimed to unlock mysteries of human body, dies at 77 - The San Diego Union-Tribune

Amgen : Cancer Writer and Researcher Siddartha Mukherjee Shares Novel Ideas on Battling the "Emperor" – Marketscreener.com

Siddhartha Mukherjee is best known as the author of The Emperor of All Maladies, a 'biography' of cancer that earned the Pulitzer Prize for nonfiction in 2011. But as Amgen staff who attended a recent online lecture hosted by Amgen's Global Research can tell you, Mukherjee's interest in cancer isn't confined to just writing about it. As a scientist, a physician, and an entrepreneur who has founded multiple companies, Mukherjee is advancing a host of out-of-the-box approaches for treating cancer. In many cases, these novel therapeutic ideas are informed by the love of history reflected in his books.

'There is a paper by Stephen Paget from the 1800s that I make all my students read,' said Mukherjee. 'Paget coined the term 'seed and soil,' and he wondered whether obsessing about the seed-in this case the cancer cell-was done at the cost of obsessing about the soil, or the environment in which the cancer cell flourishes and grows. What features of the environment allow certain cancers to grow, and can we change the environment of cancer rather than changing the seed?'

Modern cancer research, with its focus on the genetics of tumors, is very much a seed-centric approach to disease, observed Mukherjee. He likened this focus to the famous New Yorker cartoon, 'The View from Ninth Avenue,' where Manhattan looms large in the foreground and the rest of the world looks like blips on the horizon.

'In the 1990s and 2000s, as we learned more about the cancer genome, the view of cancer biology was like that New Yorker's view,' he said. 'All we could see was the genome, and the things I was interested in-the cell biology, the microenvironment-were blips on the horizon. But cancer is not something that happens in a vacuum. What can we understand about the host?'

Deleting host antigens to make cancer stand out

Mukherjee's seed-and-soil approaches to cancer have yielded several new treatment approaches with intriguing potential. For example, one frustration in cancer drug design is the dearth of biological targets found on cancer cells but largely absent from healthy tissues. Consequently, many agents that are potent tumor killers can't be dosed as aggressively as needed due to side effects.

'Cancer is a perverted version of our normal cells,' he noted. 'So how can we attack cancer when cancer shares so many features of normalcy?' One potential solution is to remove antigens from normal cells-'in other words, change the host to make the cancer stand out. We know from genetics that some antigens are not absolutely required for survival, because there are people who are walking around without them.' Those antigens can now be deleted from normal cells using tools like CRISPR.

In AML (acute myeloid leukemia), all the cancerous cells express an antigen called CD33, but so do normal hematopoietic stem cells that give rise to mature immune cells. Experiments in mice and non-human primates have confirmed that if you delete the gene for CD33 from blood stem cells, these cells will still mature into normal, fully functioning immune cells, which are no longer susceptible to cancer therapies that target CD33.

Mukherjee is the scientific board chair of a new company that is planning to test this treatment paradigm in AML patients. 'These patients would be receiving an allogenic transplant of stem cell anyway,' he observed. 'The idea is to infuse them with CD33-deleted cells and then use a CD33 therapy to kill the cancer cells and spare the normal cells.' Several other nonessential human antigens can also be deleted to further differentiate tumor cells and reduce the risk that these cells can survive through mutations that delete a target antigen.

Asking the cancer itself what drugs would kill it

Mukherjee described several other ideas that are being advanced by biotech companies he helped to launch, including one that borrowed a page from antimicrobial therapy. 'If you get an infection in the hospital, we culture and test the bacteria to figure out what antibiotics they are sensitive to. We're doing the same with cancer by asking, 'What can the cancer tell you about its sensitivities? It sounds like a simple idea but it's quite complex to enact.'

In practice, this approach takes a biopsy from a patient with a hard-to-treat cancer and grows the tumor cell organoids, or mini tissues. The organoids are separated into hundreds of wells on plates, which are used to screen thousands of drugs to find those that are best at killing the patient's cancer. The effectiveness of treatments can vary from one patient to another with the same cancer, and the best drugs may be ones that wouldn't normally be used against that tumor type. Early and encouraging results have been seen in one patient, and a trial is being planned to evaluate this approach in more patients with metastatic disease.

In his Amgen lecture, Mukherjee described two other potential new treatment paradigms-one that treats cancer by altering the patient's immune environment and another that adjusts the metabolism to mitigate against the potential side effects that limit a promising class of cancer drugs.

Mukherjee closed his lecture by saying that he feels personally gratified that all of the ideas he discussed and several others have given rise to new companies and clinical trials. 'I like making medicines. It is one of the most profound and most beautiful things that humans do'.

Read this article:
Amgen : Cancer Writer and Researcher Siddartha Mukherjee Shares Novel Ideas on Battling the "Emperor" - Marketscreener.com

Could CRISPR-engineered crops help solve the world’s food crisis? – New Food

Dr Feng Zhang, a pioneer in plant genome editing, is developing CRISPR-modified plants as a potential solution to the challenge of feeding our rapidly growing population. Here, CRISPR technology expert, Mollie Schubert, discusses his work.

CRISPR technology has emerged as a much more efficient, precise, and simple technology for crop engineering

With the United Nations (UN) projecting that the world population will reach 8.5 billion by the year 2030 and 9.7 billion by 2050, an increasingly pressing question is how will we provide enough food for this many people without putting more pressure on our already strained resources and planet? One potential solution being investigated is that of crop plants, which can now be precisely enhanced using advanced technologies like CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) engineering, to be more resilient to pests and climatic stresses, as well produce higher yields.

As early as 2007, Dr Feng Zhang, PhD, an Assistant Professor at the Center for Precision Plant Genomics and Department of Plant and Microbial Biology at the University of Minnesota, was looking into ways of improving genome editing technologies for the genetic engineering of plants. Towards the end of 2009, he co-developed an important genetic engineering technology based on transcription activator-like effector nucleases (TALEN), which are enzymes that can be tailored to cut specific sequences of DNA. TALENs greatly improved the efficiency and precision of genetic engineering in plants. Since then, genome editing technologies have evolved rapidly, and CRISPR has emerged as a much more efficient, precise and simple technology to use. Now, Dr Zhang and his team use CRISPR exclusively for their research into improving food crops. He continues to lead projects aimed at not only developing better crops but also at refining CRISPR technologies for application in plants.

The genetic engineering of plant cells has posed some novel challenges compared to working with animal and human cells. For one, the plant genomes tend to contain more adenine (A) and thymine (T) bases than animal or human genomes. This means that Cas9, the CRISPR enzyme first discovered and primarily used in CRISPR experiments, is not able to target large portions of typically AT-rich plant genomes. In addition, plants are routinely grown at lower temperatures than mammalian cells and Cas9 is less active at these lower temperatures. To expand the CRISPR toolkit for scientists such as Dr Zhang, experts have been working to develop and optimize alternative Cas enzymes. Cas12a (formerly known as Cpf1) is one such example.

Cas12a is a CRISPR enzyme that targets AT-rich regions of DNA. However, the original form or wild type version of this enzyme has proven inefficient as its nuclease activity is substantially lower than that of Cas9. To address this characteristic, we created many mutant versions of Cas12a, which were then screened for high-activity variants, using an unbiased bacterial screen. The result was Alt-R A.s. Cas12 Ultra, an enzyme that is as active as Cas9, which is also able to withstand a broad range of temperatures making it ideal for both animal and plant cells.

IDTs Alt-R CRISPR Cas12a (Cpf1) system

Another challenge of plant cell biology for genetic engineering is the presence of the cell wall, a layer of tough cellulose outside of the cell. While it is crucial to protect the cell and provide structural support, the cell wall imposes a barrier to reagents used in genetic engineering, preventing them from entering the cell. One way that Dr Zhang and his team have overcome this is to enzymatically remove the cell wall, leaving the cell surrounded only by its cell membrane. This protoplast cell is thus much more permeable to reagents and as such, more closely resembles a mammalian cell. By working with protoplasts, CRISPR engineering can be performed at much higher throughput, which will be necessary for applications like functional genomic and expedited crop improvement.

A final hurdle in delivering genetic engineering reagents efficiently to precisely target DNA has been overcome through the direct delivery of ribonucleoproteins (RNPs). These greatly simplify genetic engineering and are used by Dr Zhang and his team as a key component of their experiments. Moreover, being commercially available, RNPs provide reliable editing precision and improve the reproducibility of CRISPR experiments. A further advantage of RNPs is that they facilitate genome editing in such a way that results in a transgene-free product. This means that the product will likely not be designated as a genetically modified organism (GMO) by regulatory agencies.

All these advances and refinements are applied by Dr Zhang to the development of new and improved crop plants. He and his team are using CRISPR to engineer crops with important traits, such as greater yield. Crops with higher productivity is the number one goal of plant breeders, as this is and always has been and increasingly will be essential for all crops. Beyond productivity, variants are also being developed with the other desirable traits, such as herbicide tolerance and insect resistance. A growing concern is also being addressed through the development of crops that are better able to cope with climatic stresses, such as variants with drought or flood tolerance.

Despite all the research and development going into the improvement of crop plants, there is yet one other critical consideration. Public acceptance of foods produced using CRISPR-engineered crops is absolutely vital if this avenue of research is to help solve the worlds food crisis. To achieve this, scientists, including Dr Zhang, are going beyond the engineering of traits, such as insect resistance in crops. He is focused on developing crops that are better for human health, for example with soybeans that contain no trans-fat but more healthy fat that is crucial for protecting the heart and brain cells. By putting consumers first and focusing on the development of traits that offer health benefits for consumers, the hope is the threshold for public acceptance will be lower. This will of course need to be coupled by information and education so that consumers are empowered to make informed decisions.

In fact, the first gene-edited food is already on the market. An oil made from soybeans that have been engineered using TALENs to contain no trans fats is being sold to companies in the food service industry. This non-GMO oil has been developed and manufactured by Calyxt, the Minnesota-based company that Dr Zhang co-founded many years ago. Although he has since moved on to pursue research in the public sector, he continues to watch with interest the anticipated launches of Calyxt pipeline products like high-fibre wheat and reduced-browning potatoes. We too look forward to seeing what Dr Zhang and his team will come up with next, both in terms of advancing CRISPR technologies for plant engineering, as well as hardier and more productive food crops that could help feed the world.

About the author

Mollie Schubert is a Staff Scientist in the molecular genetics research group at Integrated DNA Technologies (IDT). Mollie received her masters degree in biochemistry from Iowa State University and has been at IDT since 2013, where she has focused on studying CRISPR gene editing. Specifically, this has included high-throughput screening of CRISPR-Cas9 guides for the development of a site selection tool, optimising the composition and delivery of synthetic RNA reagents complexed to recombinant CRISPR nucleases, and developing methods for efficient gene editing with a focus on improvements to homology directed repair.

Read the rest here:
Could CRISPR-engineered crops help solve the world's food crisis? - New Food

To Understand the Machinery of Life, a UArizona Scientist Breaks it on Purpose – UANews

By Daniel Stolte, University Communications

Today

"I'm fascinated with life, and that's why I want to break it."

This is how Betl Kaar, an assistant professor at the University of Arizona with appointments in the Department of Molecular and Cellular Biology, Department of Astronomy and the Lunar and Planetary Laboratory, describes her research. What may sound callous is a legitimate scientific approach in astrobiology. Known as ancestral sequencing, the idea is to "resurrect" genetic sequences from the dawn of life, put them to work in the cellular pathways of modern microbes think Jurassic Park but with extinct genes in place of dinosaurs, and study how the organism copes.

In a recent paper published in the Proceedings of the National Academy of Sciences, Kaar's research team reports an unexpected discovery: Evolution, it seems, is not very good at multitasking.

Kaar uses ancestral sequencing to find out what makes life tick and how organisms are shaped by evolutionary selection pressure. The insights gained may, in turn, offer clues as to what it takes for organic precursor molecules to give rise to life be it on Earth or faraway worlds. In her lab, Kaar specializes in designing molecules that act like tiny invisible wrenches, wreaking havoc with the delicate cellular machinery that allows organisms to eat, move and multiply in short, to live.

Kaar has focused her attention on the translation machinery, a labyrinthine molecular clockwork that translates the information encoded in the bacteria's DNA into proteins. All organisms from microbes to algae to trees to humans possess this piece of machinery in their cells.

"We approximate everything about the past based on what we have today," Kaar said. "All life needs a coding system something that takes information and turns it into molecules that can perform tasks and the translational machinery does just that. It creates life's alphabet. That's why we think of it as a fossil that has remained largely unchanged, at least at its core. If we ever find life elsewhere, you bet that the first thing we'll look at is its information processing systems, and the translational machinery is just that."

So critical is the translational machinery to life on Earth that even over the course of more than 3.5 billion years of evolution, its parts have undergone little substantial change. Scientists have referred to it as "an evolutionary accident frozen in time."

"I guess I tend to mess with things I'm not supposed to," Kaar said. "Locked in time? Let's unlock it. Breaking it would lead the cell to destruction? Let's break it."

The researchers took six different strains of Escherichia coli bacteria and genetically engineered the cells with mutated components of their translational machinery. They targeted the step that feeds the unit with genetic information by swapping the shuttle protein with evolutionary cousins taken from other microbes, including a reconstructed ancestor from about 700 million years ago.

"We get into the heart of the heart of what we think is one of the earliest machineries of life," Kaar said. "We purposely break it a little, and a lot, to see how the cells deal with this problem. In doing this, we think we create an urgent problem for the cell, and it will fix that."

Next, the team mimicked evolution by having the manipulated bacterial strains compete with each other like a microbial version of "The Hunger Games." A thousand generations later, some strains fared better than others, as was expected. But when Kaar's team analyzed exactly how the bacteria responded to perturbations in their translational components, they discovered something unexpected: Initially, natural selection improved the compromised translational machinery, but its focus shifted away to other cellular modules before the machinery's performance was fully restored.

To find out why, Kaar enlisted Sandeep Venkataram, a population genetics expert at the University of California, San Diego.

Venkataram likens the process to a game of whack-a-mole, with each mole representing a cellular module. Whenever a module experiences a mutation, it pops up. The hammer smashing it back down is the action of natural selection. Mutations are randomly spread across all modules, so that all moles pop up randomly.

"We expected that the hammer of natural selection also comes down randomly, but that is not what we found," he said. "Rather, it does not act randomly but has a strong bias, favoring those mutations that provide the largest fitness advantage while it smashes down other less beneficial mutations, even though they also provide a benefit to the organism."

In other words, evolution is not a multitasker when it comes to fixing problems.

"It seems that evolution is myopic," Venkataram said. "It focuses on the most immediate problem, puts a Band-Aid on and then it moves on to the next problem, without thoroughly finishing the problem it was working on before."

"It turns out the cells do fix their problems but not in the way we might fix them," Kaar added. "In a way, it's a bit like organizing a delivery truck as it drives down a bumpy road. You can stack and organize only so many boxes at a time before they inevitably get jumbled around. You never really get the chance to make any large, orderly arrangement."

Why natural selection acts in this way remains to be studied, but what the research showed is that, overall, the process results in what the authors call "evolutionary stalling" while evolution is busy fixing one problem, it does at the expense of all other issues that need fixing. They conclude that at least in rapidly evolving populations, such as bacteria, adaptation in some modules would stall despite the availability of beneficial mutations. This results in a situation in which organisms can never reach a fully optimized state.

"The system has to be capable of being less than optimal so that evolution has something to act on in the face of disturbance in other words, there needs to be room for improvement," Kaar said.

Kaar believes this feature of evolution may be a signature of any self-organizing system, and she suspects that this principle has counterparts at all levels of biological hierarchy, going back to life's beginnings, possibly even to prebiotic times when life had not yet materialized.

With continued funding from the John Templeton Foundation and NASA, the research group is now working on using ancestral sequencing to go back even further in time, Kaar said.

"We want to strip things down even more and create systems that start out as what we would consider pre-life and then transition into what we consider life."

View post:
To Understand the Machinery of Life, a UArizona Scientist Breaks it on Purpose - UANews

Avobis Bio and Vineti announce strategic collaboration to support new implantable cell therapies addressing debilitating conditions – GlobeNewswire

NEWARK, Del. and SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Today, Avobis Bio, LLC (Avobis Bio), a clinical-stage regenerative therapy company specializing in the development of implantable cell therapies, and Vineti, Inc., the leading software platform for personalized therapeutics, announced a new collaboration to advance and scale Avobis Bios innovative cell therapy pipeline.

Avobis Bios first therapeutic involves harvesting and processing a patient's own mesenchymal stem cells for the treatment of perianal fistulas, an often debilitating condition that afflicts patients with Crohn's disease. Personalized therapies require a software system to manage the complex value chain associated with autologous, patient-based therapies and Vineti provides the leading digital software platform to align and efficiently manage this process.

Avobis Bio is working towards a major leap forward in implantable cell therapy for treating debilitating conditions and alleviating patient suffering, said Tiffany Brown, General Manager, Avobis Bio. Our clinical-phase pipeline will advance more quickly with the support of a leading software platform that solves many of the infrastructure challenges facing personalized treatments.

Through this collaboration, Vinetis software platform will help Avobis Bio advance its clinical trial by supporting cell collection scheduling, logistics orchestration, and traceability for each patients individual drug product.

Vinetis Personalized Therapy Management platform (PTM) is the first cloud-based software platform to help safely and efficiently move patient-based personalized therapies through clinical development and into mainstream medicine at scale. The Vineti platform configurable, cloud-based, secure and scalable brings the best of enterprise software to advanced therapies. The Vineti solution automates traceability for personalized therapies, enables sophisticated, efficient treatment scheduling and manufacturing, and helps ensure conformation with regulations and standards.

Vineti is honored to support Avobis Bio in its work to develop a new generation of implantable cell therapies, said Amy DuRoss, CEO and Co-founder, Vineti. Avobis Bio has created a remarkable new approach for patients in true need. We are very excited to help them scale their treatments and reach more patients with few other options.

About Avobis Bio, LLC

Avobis Bio is dedicated to advancing the development of implantable cell therapies to treat debilitating conditions without a cure. The investigational portfolio explores the use of mesenchymal stem cells combined with bioabsorbable scaffolds to enhance the effectiveness of cells in stimulating the body to heal. Avobis Bio was formed as a joint venture between Mayo Clinic and W. L. Gore & Associates to combine capabilities in clinical care, cell biology, materials science and commercialization of medical products. In a tribute to the patients it serves and the power of their own mesenchymal stem cells, Avobis Bio draws its name from the Latin a vobis, meaning from you or by you.

About Vineti, Inc.

Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital Personalized Therapy Management (PTM) platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers worldwide in 2019, on behalf of multiple biopharmaceutical partners. In 2019, the World Economic Forum selected Vineti as a global Technology Pioneer.

Media Contacts

VinetiStacy Henrypress@vineti.com

Avobis Bio, LLCPaul Fischerinformation@avobisbio.com

Original post:
Avobis Bio and Vineti announce strategic collaboration to support new implantable cell therapies addressing debilitating conditions - GlobeNewswire